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The candidate prostate cancer susceptibility gene HPC2/ELAC2 has two common coding polymorphisms: (Ser?Leu 217) and
(Ala?Thr 541). The Thr541 variant in the HPC2/ELAC2 gene has previously been reported to be at an increased frequency in
prostate cancer cases. To evaluate this hypothesis we genotyped 432 prostate cancer patients (including 262 patients
diagnosed 455 years) and 469 UK, population based control individuals with no family history of cancer. We found no
signiﬁcant difference in the frequencies of Thr541-containing genotypes between cases and controls (OR=1.41, 95% CI 0.79–
2.50). The association remained non-signiﬁcant when the analysis was restricted to cases divided by age of onset into those
diagnosed 455 years (OR=1.50, 95% CI 0.79–2.85) or to patients diagnosed 455 years (OR=1.27, 95% CI 0.59–2.74).
We conclude that any association between the Thr541 variant and prostate cancer is likely to be weak.
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The HPC2/ELAC2 gene, located on chromosome 17p11.2 was
recently mapped and characterised (Tavtigian et al, 2001). The
ELAC2 gene product has an amino acid sequence similarity to
DNA interstrand crosslink repair proteins (PSO2, SNM1) and the
73-kD subunit of mRNA 3' end cleavage and polyadenylation
speciﬁcity factor (CPSF73). Tavtigian et al (2001) reported linkage
to prostate cancer (PrCa) in this region, using a set of 33 extended
multiple case pedigrees from Utah. They obtained a maximum two
point lod score of 4.5 at marker D17S1289 (y=0.07) and a three
point lod score of 4.3 using the markers D17S1289 and D17S921
(y=0.10) using a recessive model. Mutational analysis of HPC2/
ELAC2, using an extended PrCa family set of 127 pedigrees with
individual family lod scores of 51o r4six cases sharing a haplo-
type, revealed that a subset of individuals in one family carried a
germline frameshift mutation (1641insG). A common missense
variant (serine to leucine at amino acid 217) was found in 13%
of PrCa cases vs 9% of unaffected pedigree members and 6% of
controls (Tavtigian et al, 2001). The authors also reported a second
non conservative missense change in the ELAC2 gene, alanine to
threonine at amino acid 541, that lies at the amino border of
the histidine motif in the ELAC2 gene (Tavtigian et al, 2001).
These two polymorphisms are in strong linkage disequilibrium,
such that the Thr541 allele only occurs on a Leu217 background.
The authors obtained a higher frequency of Thr541 carriers in
PrCa cases in their families than in ‘divergent controls’ (unaffected
spouses from other cancer families) (OR=3.1, P=0.022), though
not when compared with unaffected individuals in the PrCa
families. Tavtigian et al (2001) postulate that the Leu217/Thr541
haplotype results in more functional disruption of the protein than
the commoner Leu217/Ala541 haplotype. An association between
the Thr541 allele and PrCa was also reported by Rebbeck et al
(2000), who estimated an odds ratio for PrCa of 2.37 (95% CI
1.06–5.29) associated with carrying the Thr541 allele. Among the
266 male control subjects (matched for age and race), a Thr541
allele frequency of 2.9% and a Leu217 allele frequency of 31.6%
were reported. Suarez et al (2001) also found a signiﬁcantly higher
frequency of Thr541 alleles in PrCa cases than in controls (OR=3.6,
95% CI 1.8–7.3) in a study of 257 multiplex PrCa sibships and
355 controls. However, four recently published studies (Ro ¨kman
et al, 2001; Vesprini et al, 2001; Wang et al, 2001; Xu et al,
2001) reported no evidence for an association between the
Leu217 and Thr541 variants and PrCa risk. Xu et al (2001) also
reported no linkage at HPC2 after genotyping 159 hereditary PrCa
families (with at least three affected family members) and analysing
them using both parametric and nonparametric methods.
In an attempt to conﬁrm or refute the association of HPC2 and
PrCa, and in addition to investigate any association with age of
onset, we have genotyped these variants in a series of 432 PrCa
patients from the UK, including 262 patients diagnosed 455 years,
and 469 controls.
MATERIALS AND METHODS
PrCa patients
This study was conducted on prostate cancer samples from patients
treated in the UK. We obtained 432 blood samples from two series
of PrCa Patients via consultants collaborating in the Cancer
Research UK (formerly Cancer Research Campaign)/British Pros-
tate Group (CRC/BPG) UK Prostate Familial Cancer Study
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(RMNHST) PrCa clinic. The PrCa cases were collected in two sets.
Series (I) A national study of early onset PrCa, selecting patients
diagnosed at age 455 years; patients were referred into this study
through collaborating clinicians across the UK (The CRC/BPG
Study). Patients were not selected on the basis of their family
history. The average age of diagnosis of the PrCa patients was 51
years (range 24–55 years).
Series (II) A systematic series of PrCa cases, ascertained through
the Urology Unit of the Royal Marsden Hospital, London, UK over
the period 1992–1993. These patients were unselected for age or
family history. The average age of diagnosis of the PrCa patients
was 69 years (range 55–80 years).
In the analysis patients were subdivided into those diagnosed
455 years (n=262) and those diagnosed 455 years (n=170). For
the purpose of this analysis we excluded non-Caucasian patients;
Controls
We had two control series available for analysis. Series (1)
comprised spouses of patients enrolled in an UK population based
study of colorectal cancer (number available=285; 136 female, 149
male; number informative=276). Of these informative controls, 142
were male and 134 were female. Series (2) was selected from the
controls in an UK population based study of breast cancer diag-
nosed 445 years age (number available=223, number
informative=193;). The controls in series (2) were female. All
controls were cancer free at the time of ascertainment. A total of
469 control samples were genotyped.
DNA extraction
DNA was extracted from blood samples by routine methods with
the inclusion of a second proteinase K digestion at 508C. (Edwards
et al, 1997). DNA was dissolved in 0.2 to 0.4 ml of water (BDH,
Poole, UK) and stored at 7208C until required.
PCR and genotyping
Ser217Leu variant The PCR primers used were designed by
Tavtigian et al (2001) and also published by Rebbeck et al
(2000). The region containing the Ser217Leu variant was ampliﬁed
as described by Rebbeck et al (2000) using a 658–518C touchdown
protocol. The 335 bp PCR product (15 ml) was digested overnight
with 15 U Taq I a (NEB RO149L) at 658C. Genotypes were visua-
lised on a 2.5% Agarose Gel (Metaphor Agarose). The PCR
product sizes after digestion were either 173+162 bp, for the Ser/
Ser genotype or 335 bp for the uncut Leu/Leu genotype or
335+173+162 bp for the Ser/Leu genotype.
Ala541Thr variant The primers used to amplify the region of
the Ala541Thr variant were described by Rebbeck et al (2000).
The PCR product was digested overnight with 2 U Fnu4HI
(NEB, R0178L) at 378C. The digested 495 bp PCR product was
visualised as either 250+110 bp fragment (Ala/Ala genotype) or
as 250+162+110 bp (Ala/Thr genotype) always with three smaller
fragments (34, 49, 52 bp). We did not observe any Thr/Thr geno-
types (250+162+49+34 bp).
Analysis
Analyses of genotype frequencies for each polymorphism were
based on all cases and controls successfully typed for each poly-
morphisms, whereas analyses of combined genotypes at codons
217 and 541 were based on individuals successfully genotyped at
both loci (Table 2), so the numbers of cases and controls differ
slightly between analyses. Differences in genotype frequencies
between cases and controls were tested using standard chi-squared
tests. Odds ratios and conﬁdence limits were calculated using stan-
dard methods. Trends in genotype frequencies by age at diagnosis
were tested using logistic regression. The meta-analysis of genoty-
pic risks over all studies was also conducted using logistic
regression, treating each study as a separate stratum.
RESULTS
The estimated allele frequencies in the combined control series
were 2.4% for the Thr541 allele and 28.3% for the Leu217 allele
(based on 457 controls, successfully genotyped for both poly-
morphisms). In agreement with previous studies we observed a
Thr541 allele only in the presence of a Leu217 allele. The control
frequency of the Leu217 allele (32 vs 26%) and of the Thr541 allele
(3.4 vs 1.6%) was higher in series (2) than in series (1) controls.
Neither difference was, however, statistically signiﬁcant (w
2=2.28,
P=0.13 and w
2=3.51, P=0.06) respectively and we therefore
combined our control series for the main analysis. There was also
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Table 1 All Ala541 homozygotes compared to individuals who carried the Thr541 allele
Controls
Cases 455 years Cases 455 years
All cases
Ser217Leu genotype Ala541Thr genotype No. (%) No. (%) OR (CI 95%) No. (%) OR (CI 95%) OR (CI 95%)
Any A/A 447 (95%) 244 (93%) 1.00 160 (94%) 1.00 1.00
Any Any T 22 (5%) 18 (7%) 1.50 (0.79–2.85) 10 (6%) 1.27 (0.59–2.74) 1.41 (0.79–2.50)
Table 2 Case–control comparison of HPC2/ELAC2 genotypes
Controls
Cases 455 years Cases 455 years
All cases
Ser217Leu genotype Ala541Thr genotype No. (%) No. (%) OR (CI 95%) No. (%) OR (CI 95%) OR (CI 95%)
S/S A/A 242 (53%) 112 (46%) 1.00 86 (52%) 1.00 1.00
S/L A/A 155 (34%) 97 (40%) 1.35 (0.96–1.89) 52 (31%) 0.94 (0.67–1.40) 1.17 (0.87–1.57)
L/L A/A 38 (8%) 17 (7%) 0.97 (0.52–1.79) 18 (11%) 1.33 (0.72–2.45) 1.13 (0.69–1.86)
Any Any T 22 (5%) 18 (7%) 1.77 (0.91–3.43) 10 (6%) 1.27 (0.58–2.79) 1.56 (0.87–2.81)
‘Any’ describes either the genotype S/L or L/L (in Ser217Leu column) – S/S was not observed together with the A541T variant; ‘Any T’ describes the genotype A/T, as no
homozygous Thr541 genotypes were observed.
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females within control series (1).
To do the main calculations for the association between the
Thr541 variant and PrCa risk, another 18 PrCa cases diagnosed
455 years and also four PrCa cases diagnosed 455 years, that
only failed for the Ser217Leu genotype were included in the
analyses. We found no signiﬁcant difference in the frequency of
Thr541 containing genotypes between cases and controls (OR
1.41, 95% CI 0.79–2.50, Table 1). This remained true when atten-
tion was restricted to patients diagnosed 455 years (OR 1.50, 95%
CI 0.79–2.85) or to patients diagnosed at 455 years (OR 1.27,
95% CI 0.59–2.74). There were also no signiﬁcant differences in
the genotype frequencies of the Ser217Leu polymorphism. Esti-
mated odds ratio for the genotypes based on both
polymorphisms (Leu217/Thr541 genotypes; S/L/A/T, L/L/A/T) are
shown in Table 2. The odds ratio for Thr541 carriers, compared
with Ser217/Ala541 homozygotes was slightly elevated (1.56, 95%
CI 0.87–2.81) but still not signiﬁcantly different from 1.00. We
also tested for a trend in Thr541 frequency with age at diagnosis,
but found no signiﬁcant effect.
DISCUSSION
We attempted to replicate the association between Thr541 and
PrCa risk reported by Tavtigian et al (2001) and Rebbeck et al
(2000), but found no signiﬁcant effect in our dataset. The esti-
mated effect in our study (odds ratio 1.41) was in the same
direction as the previous studies, but the magnitude of the effect
was markedly smaller. However conﬁdence limits on these odds
ratios are still wide, and the results are still consistent with a
two-fold increased risk.
We also analysed the data on the basis of combined Ser217Leu
and Ala541Thr genotypes. We found a slightly higher odds ratio
for Thr541 carriers compared with Ser217/Ala541 homozygotes
(OR 1.56, 95% CI 0.87–2.81; Table 2) and compared with all
other Ala541 homozygotes (OR 1.41, 95% CI 0.79–2.50, Table
1). This difference is a result of the slightly (but not signiﬁcantly)
higher frequency of Ser217/Leu217 carriers in PrCa cases, a trend
which is more marked in cases diagnosed 455 years (OR=1.35,
95% CI 0.96–1.89). This effect was also seen by Tavtigian et al
(2001) and Rebbeck et al (2000). If these were true differences, they
would imply a small PrCa risk associated with the Leu substitution
and a larger risk associated with Thr541. However, the Leu217
effect is not signiﬁcant in any study.
A notable feature of our study was the large proportion of
cases (n=262) diagnosed at 455 years of age, which we ascer-
tained through an UK national study of early onset PrCa. The
familial risk of PrCa is much higher at young ages (Carter et
al, 1992) and one might therefore expect any effect of HPC2 to
be stronger in this age group. Moreover, screen detected disease
is almost entirely absent in this group. The estimated odds ratio
associated with Thr541 was higher in this age group, but it was
still less than two and not signiﬁcantly different from that in
the older age group (OR 1.77, 95% CI 0.91–3.43 vs 1.27, 95%
CI 0.58–2.79).
Suarez et al (2001) did not ﬁnd a signiﬁcant difference in the
frequency of Ser217Leu variants between cases and controls
(w
2=1.79; P=0.18) but found a signiﬁcantly greater frequency of
the Ala541Thr variant in cases than in controls (w
2=7.13;
P=0.008); this gives an estimated OR of 3.6 (95% CI 1.8–7.3).
The study genotyped 257 PrCa patients (multiplex sibships) and
355 race matched healthy unrelated controls. No excess clustering
of the Thr541 allele was found within the multiplex families which
suggested no evidence for linkage of PrCa to the HPC2/ELAC2
gene.
Four other recent studies showed a negative risk association of
HPC2 with PrCa. Xu et al (2001) exclude a major contribution
of HPC2/ELAC2 as a high-prevalence, high-penetrance major gene
for PrCa after performing linkage analysis in multiple case PrCa
families and mutation screening (using DHPLC) of all coding
exons of the gene in 93 probands. The study also genotyped 159
PrCa probands with a family history (hereditary prostate cancer,
HPC), 249 PrCa patients with sporadic PrCa and 211 unaffected
male control subjects. The results for Thr541 carrier frequencies
were 10.5% for HPC patients, 9.0% for patients with sporadic PrCa
and 9.0% for the control subjects. (HPC OR=1.37, 95% CI 0.61–
3.11 for low risk allele S/S/A/A)
In another recently published study by Vesprini et al (2001), 431
screen detected PrCa patients with an elevated serum-PSA level
(44.0 ng ml
-1) were genotyped for the two missense mutations
Ser217Leu and Ala541Thr. Also 531 men, who underwent prostatic
biopsy but had no evidence of invasive cancer were genotyped and
were then used as male controls. Another control population
consisted of 922 healthy, unselected women from the same popula-
tion. The group found a similar Thr541allele frequency between 6.3
and 6.8% for all their patients and controls respectively, which lead
to the conclusion that the Thr541 variant is unsuitable for use as a
screening method for PrCa patients with a raised PSA. There was
no association between the Ala541Thr variant and the risk of
screen detected PrCa (OR 1.10; 95% CI 0.48–2.50; P=0.84).
Ro ¨kman et al (2001) genotyped 107 HPC cases, 467 unselected
PrCa cases and 223 benign prostatic hyperplasia (BPH) cases and
568 healthy male blood donors for the two HPC2 variants
Leu217 and Thr541. The study found no difference in the frequen-
cies of Leu217 and Thr541 in HPC patients, unselected PrCa
patients or the control group (42–54% and 7.5%) respectively,
but a slightly higher frequency of the Thr541 variant was observed
in the BPH cases (OR=1.73, 95% CI 1.04–2.87). The group also
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Table 3 Meta analysis comparing results of the seven published association studies (A541T) together with the current study
Cases [n] Controls [n]
Study Ala/Ala Any Thr Ala/Ala Any Thr OR (95% CI)
Tavtigian et al, 2001
a 387 42 143 5 3.10 (1.20–8.00)
Rebbeck et al, 2000 332 27 249 9 2.25 (1.04–4.87)
Vesprini et al, 2001 404 27 1408 97 0.97 (0.62–1.51)
Suarez et al, 2001 232 25 342 13 2.83 (1.42–5.66)
Ro ¨kman et al, 2001 531 43 526 42 1.01 (0.65–1.58)
Wang et al, 2001 399 46 450 52 1.00 (0.66–1.52)
Xu et al, 2001
b 322 33 166 16 1.06 (0.57–1.99)
Meitz et al, 2001 404 28 447 22 1.41 (0.79–2.50)
Combined 3011 271 3731 256 1.27 (1.06–1.54)
aComparison with ‘divergent controls’ (married-in spouses from other cancer families).
bXu et al (2001) present an age-adjusted OR of 1.09 (95% CI 0.58–2.05). For consistency
with the other studies, the unadjusted OR (which is almost identical) is presented here.
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SSCP and found the variant Glu622Val. The results showed an
almost three-fold increased risk of PrCa in carriers of the Val622
mutation compared to non-carriers (OR=2.94, 95% CI 1.05–8.23).
Wang et al (2001) found no association of Ser217Leu and
Ala541Thr with PrCa risk by genotyping 446 PrCa patients from
164 families and 502 population based controls (OR=1.04; 95%
CI 0.57–1.89). The Leu217 frequency in PrCa patients was
32.3% and in controls 31.8%. The frequency of the Thr541 variant
was 5.4% in patients vs 5.2% in controls.
In order to evaluate the overall evidence for an effect of the
Ala541Thr polymorphism on PrCa risk, we performed a meta-
analysis based on the results of the seven published studies
(Rebbeck et al, 2000; Ro ¨kman et al, 2001; Suarez et al, 2001; Tavti-
gian et al, 2001; Vesprini et al, 2001; Wang et al, 2001; Xu et al,
2001), together with the current study (Table 3). The estimated
odds ratio for the Thr541 carriers compared with all other geno-
types was 1.27 (95% CI 1.06–1.54, P=0.012). However, there is
signiﬁcant evidence of heterogeneity in the odds ratio estimates
among the studies (w2
7=16.18, P=0.024). If the Vesprini et al
(2001) data (which is based on screen detected cancers and
controls undergoing screening) is excluded, the estimated odds
ratio was 1.36 (95% CI 1.10–1.68, P=0.004). However, if the initial
hypothesis-generating studies of Tavtigian et al (2001) and Rebbeck
et al (2000) are also excluded, the evidence is much weaker (OR
1.21, 95% CI 0.96–1.53, P=0.10).
We conclude that the HPC2 variants are associated with, at
most, a moderate increased risk of PrCa. In particular Thr541 is
unlikely to be associated with a risk of more than 1.5-fold.
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